Concert Pharmaceuticals (NASDAQ:CNCE)‘s stock had its “buy” rating reiterated by analysts at Mizuho in a research note issued to investors on Friday, AnalystRatings.com reports. They presently have a $23.00 target price on the biotechnology company’s stock. Mizuho’s target price indicates a potential upside of 117.19% from the stock’s current price.
CNCE has been the topic of several other research reports. BidaskClub upgraded Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 8th. HC Wainwright restated a “buy” rating and issued a $26.00 price target on shares of Concert Pharmaceuticals in a research note on Friday, May 3rd. Zacks Investment Research upgraded Concert Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, May 1st. TheStreet downgraded Concert Pharmaceuticals from a “c-” rating to a “d” rating in a research note on Friday, March 1st. Finally, UBS Group set a $13.00 price target on Concert Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, April 10th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. Concert Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $20.00.
Concert Pharmaceuticals stock opened at $10.59 on Friday. The company has a current ratio of 20.44, a quick ratio of 20.44 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $249.62 million, a P/E ratio of -4.41 and a beta of 0.88. Concert Pharmaceuticals has a twelve month low of $9.21 and a twelve month high of $21.00.
Concert Pharmaceuticals (NASDAQ:CNCE) last posted its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.31). The company had revenue of $1.01 million during the quarter, compared to analysts’ expectations of $16.08 million. Concert Pharmaceuticals had a negative return on equity of 41.72% and a negative net margin of 7,118.04%. On average, analysts expect that Concert Pharmaceuticals will post -3.86 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the stock. Great West Life Assurance Co. Can bought a new position in Concert Pharmaceuticals in the 4th quarter valued at approximately $48,000. BNP Paribas Arbitrage SA lifted its position in Concert Pharmaceuticals by 63,200.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,431 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 4,424 shares in the last quarter. Citigroup Inc. lifted its position in Concert Pharmaceuticals by 32.5% in the 1st quarter. Citigroup Inc. now owns 7,091 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 1,739 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its position in Concert Pharmaceuticals by 452.1% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,553 shares of the biotechnology company’s stock valued at $95,000 after acquiring an additional 6,185 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Concert Pharmaceuticals in the 1st quarter valued at approximately $143,000. 71.96% of the stock is currently owned by institutional investors and hedge funds.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Read More: Investing strategies using the yield curve
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.